<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3053">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355637</url>
  </required_header>
  <id_info>
    <org_study_id>TACTIC-COVID</org_study_id>
    <secondary_id>2020-001616-18</secondary_id>
    <nct_id>NCT04355637</nct_id>
  </id_info>
  <brief_title>Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia</brief_title>
  <official_title>Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sara Varea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, prospective, controlled open label clinical trial aimed at investigating if the
      addition of inhaled corticosteroids (budesonide) reduces treatment failure (defined as a
      composite variable by the initiation of treatment with high flow-O2 therapy, non-invasive or
      invasive ventilation, systemic steroids, use of biologics (anti IL-6 or anti IL-1) and/or
      death) according to hospital standard of care guidance) at day 15 after initiation of
      therapeutic intervention.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2020</start_date>
  <completion_date type="Anticipated">October 18, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients in both arms fulfilling the criteria for treatment failure</measure>
    <time_frame>15 days after treatment</time_frame>
    <description>composite variable that includes the initiation of treatment with high flow-O2 therapy, non-invasive or invasive ventilation, systemic steroids, use of biologics (anti IL-6 or anti IL-1) and/or death) at day 15 after initiation of therapeutic intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU admission</measure>
    <time_frame>baseline, day 3, day 7, day 15, day 30</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU refusal</measure>
    <time_frame>baseline, day3, day 7, day 15, day 30</time_frame>
    <description>yes/no and reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of complications</measure>
    <time_frame>baseline, day3, day 7, day 15, day 30</time_frame>
    <description>infectious cardiovascular and /or metabolic complications as well as variation in the 7 point WHO scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lactate dehydrogenase (LDH)</measure>
    <time_frame>at baseline, day 3, day 7, day 15, day 30</time_frame>
    <description>U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C Reactive Protein (CRP)</measure>
    <time_frame>at baseline, day 3, day 7, day 15, day 30</time_frame>
    <description>mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ferritin</measure>
    <time_frame>at baseline, day 3, day 7, day 15, day 30</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>at baseline, day 3, day 7, day 15, day 30</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>leukocyte counts</measure>
    <time_frame>at baseline, day 3, day 7, day 15, day 30</time_frame>
    <description>x10^9/L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients receiving standard of care to treat their pneumonia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receiving standard of care to treat their pneumonia + inhaled budesonide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled budesonide</intervention_name>
    <description>adding budesonide to standard of care for pneumonia in COVID19 positive patients</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COVID19 positive

          -  hospitalized because of pneumonia (status #3 - #4 World Health Organization (WHO)
             scale)

          -  without contraindications to receive study treatment

          -  informed consent

        Exclusion Criteria:

          -  receiving corticoids (inhaled or systemic)

          -  receiving anti Interleukin-1 (IL-1) or anti-IL-6 drugs

          -  receiving high flow oxygen therapy

          -  receiving mechanical ventilation

          -  pregnancy

          -  participating in another intervention trial for COVID19
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alvar Agusti</last_name>
    <phone>+34932271701</phone>
    <email>aagusti@clinic.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rosa Faner</last_name>
    <phone>+34932275400</phone>
    <email>RFANER@clinic.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Marin</last_name>
      <email>amarin.germanstrias@gencat.cat</email>
    </contact>
    <investigator>
      <last_name>Alicia Marin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Dorca Sargatal</last_name>
      <email>jodorca@bellvitgehospital.cat</email>
    </contact>
    <investigator>
      <last_name>Jordi Dorca Sargatal</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salud Santos</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Sabadell-Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Ross Monserrate</last_name>
      <email>drmonserrate@tauli.cat</email>
    </contact>
    <investigator>
      <last_name>Daniel Ross Monserrate</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquim Gea Giralt</last_name>
      <email>JGea@parcdesalutmar.cat</email>
    </contact>
    <investigator>
      <last_name>Joaquim Gea Giralt</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergi Pascual</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaume Ferrer Sancho</last_name>
      <email>jjferrer@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Jaume Ferrer Sancho</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier Muñoz</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ALVAR AGUSTI</last_name>
      <phone>+34932271701</phone>
      <email>AAGUSTI@CLINIC.CAT</email>
    </contact>
    <contact_backup>
      <last_name>ROSA FANER</last_name>
      <phone>+34932275400</phone>
      <email>RFANER@clinic.cat</email>
    </contact_backup>
    <investigator>
      <last_name>ALVAR AGUSTI, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>ORIOL SIBILA, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicente Plaza</last_name>
      <email>VPlaza@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Vicente Plaza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Sara Varea</investigator_full_name>
    <investigator_title>Clinical Research Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

